An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer

Trial Profile

An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs JNJ 61610588 (Primary)
  • Indications Cervical cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 24 Aug 2017 Status changed from recruiting to discontinued due to the Janssen business decision
    • 10 Jun 2017 Biomarkers information updated
    • 23 Mar 2017 Planned End Date changed from 1 Oct 2018 to 23 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top